IGF1R pathways play a critical role in the pathogenesis of GO, and teprotumumab, a human monoclonal anti-IGF1R blocking antibody, has been approved by the FDA for the treatment of patients with GO, specifically in reducing proptosis (Kahaly et al., 2021). This evidence concerns the gene IGF1R and geroderma osteodysplastica.